Across the 2025 to 2034 projection horizon, the worldwide RAS-Targeting Drugs for Precision Oncology Market is set to register a CAGR of 11.9%.
RAS-Targeting Drugs for Precision Oncology encompasses The RAS-targeting medicines in precision oncology represents a fast-developing area dedicated to treatments that block RAS proteins—indispensable molecular promoters in aggressive forms of cancer such a. The sector has gained traction as organizations seek innovative approaches to address evolving healthcare challenges.
Market momentum is propelled by mounting appetite for advanced solutions, favorable regulatory frameworks, and robust investment in research and development across major economies.
Segmental analysis reveals differentiated growth across product categories, applications, and geographical regions, with certain niches demonstrating above-average expansion potential.
From a regional perspective, mature markets in North America and Europe continue to hold notable shares, while the Asia-Pacific region is gaining momentum through accelerated economic development and mounting investment in the sector.
Industry participants are deploying a range of strategies—including partnerships, mergers, technological investments, and portfolio diversification—to consolidate their market standing.
This comprehensive research study delivers granular insights into market sizing, trend analysis, competitive benchmarking, and forward-looking projections to support strategic decision-making for industry participants and investors.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global RAS-Targeting Drugs for Precision Oncology Market Snapshot
Chapter 4. Global RAS-Targeting Drugs for Precision Oncology Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2034
4.8. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.9. Use/impact of AI on RAS-Targeting Drugs for Precision Oncology Market Trends
4.10. Global RAS-Targeting Drugs for Precision Oncology Market Penetration & Growth Prospect Mapping (US$ Mn), 2021-2034
Chapter 5. RAS-Targeting Drugs for Precision Oncology Market Segmentation 1: By Drug Type, Estimates & Trend Analysis
5.1. Market Share by Drug Type, 2024 & 2034
5.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Drug Type:
5.2.1. Small Molecule Inhibitors
5.2.2. Biologics
5.2.3. RNA-Based Therapies
5.2.4. Combination Therapies
Chapter 6. RAS-Targeting Drugs for Precision Oncology Market Segmentation 2: Target Mutation, Estimates & Trend Analysis
6.1. Market Share by Target Mutation, 2024 & 2034
6.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Target Mutation:
6.2.1 KRAS G12C
6.2.2 KRAS G12D
6.2.3 KRAS G12V, G12R, G12S, G12A
6.2.4 HRAS and NRAS
6.2.5 Pan-RAS
Chapter 7. RAS-Targeting Drugs for Precision Oncology Market Segmentation 3: By Indication, Estimates & Trend Analysis
7.1. Market Share by Indication, 2024 & 2034
7.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Indication:
7.2.1. Non-Small Cell Lung Cancer (NSCLC)
7.2.2. Pancreatic Ductal Adenocarcinoma (PDAC)
7.2.3. Colorectal Cancer (CRC)
7.2.4. Other Cancers (e.g., HNSCC, melanoma, hematologic)
Chapter 8. RAS-Targeting Drugs for Precision Oncology Market Segmentation 4: By Route of Administration, Estimates & Trend Analysis
8.1. Market Share by Route of Administration, 2024 & 2034
8.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Route of Administration:
8.2.1. Oral
8.2.2. Intravenous
8.2.3. Other Routes
Chapter 9. RAS-Targeting Drugs for Precision Oncology Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. Global RAS-Targeting Drugs for Precision Oncology Market, Regional Snapshot 2024 & 2034
9.2. North America
9.2.1. North America RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
9.2.1.1. US
9.2.1.2. Canada
9.2.2. North America RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2021-2034
9.2.3. North America RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Target Mutation, 2021-2034
9.2.4. North America RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
9.2.5. North America RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
9.3. Europe
9.3.1. Europe RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
9.3.1.1. Germany
9.3.1.2. U.K.
9.3.1.3. France
9.3.1.4. Italy
9.3.1.5. Spain
9.3.1.6. Rest of Europe
9.3.2. Europe RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2021-2034
9.3.3. Europe RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Target Mutation, 2021-2034
9.3.4. Europe RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
9.3.5. Europe RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
9.4. Asia Pacific
9.4.1. Asia Pacific RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
9.4.1.1. India
9.4.1.2. China
9.4.1.3. Japan
9.4.1.4. Australia
9.4.1.5. South Korea
9.4.1.6. Hong Kong
9.4.1.7. Southeast Asia
9.4.1.8. Rest of Asia Pacific
9.4.2. Asia Pacific RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2021-2034
9.4.3. Asia Pacific RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Target Mutation, 2021-2034
9.4.4. Asia Pacific RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
9.4.5. Asia Pacific RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
9.5. Latin America
9.5.1. Latin America RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
9.5.1.1. Brazil
9.5.1.2. Mexico
9.5.1.3. Rest of Latin America
9.5.2. Latin America RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2021-2034
9.5.3. Latin America RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Target Mutation, 2021-2034
9.5.4. Latin America RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
9.5.5. Latin America RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
9.6. Middle East & Africa
9.6.1. Middle East & Africa Wind Turbine Rotor Blade Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.6.1.1. GCC Countries
9.6.1.2. Israel
9.6.1.3. South Africa
9.6.1.4. Rest of Middle East and Africa
9.6.2. Middle East & Africa RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2021-2034
9.6.3. Middle East & Africa RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Target Mutation, 2021-2034
9.6.4. Middle East & Africa RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
9.6.5. Middle East & Africa RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. Amgen
10.2.1.1. Business Overview
10.2.1.2. Key Drug Type/Service Overview
10.2.1.3. Financial Performance
10.2.1.4. Geographical Presence
10.2.1.5. Recent Developments with Business Strategy
10.2.2. Mirati Therapeutics
10.2.3. Revolution Medicines
10.2.4. Verastem Oncology
10.2.5. Novartis
10.2.6. Kura Oncology
10.2.7. Elicio Therapeutics
10.2.8. Jacobio Pharmaceuticals
10.2.9. Onconova Therapeutics
10.2.10. Targovax
10.2.11. Genfleet Therapeutics
10.2.12. Golden Biotechnology
10.2.13. Roche
10.2.14. Nested Therapeutics
10.2.15. AnBogen
10.2.16. AstraZeneca